Caribou Biosciences, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. Caribou is a clinical-stage genome-editing company developing allogeneic CAR-T and CAR-NK therapies. It has no products approved for sale and has generated no product-sales revenue.
Financial performance and liquidity
| Metric | Q1 2023 | Q1 2022 / comparison |
|---|---|---|
| Licensing and collaboration revenue | $3.5 million | $2.7 million; up $0.8 million (31%) |
| Research and development expense | $25.7 million | $13.9 million; up $11.8 million |
| General and administrative expense | $8.9 million | $9.6 million; down $0.7 million |
| Total operating expenses | $34.6 million | $23.5 million |
| Operating loss | $31.1 million | $20.9 million |
| Net loss; loss per share | $28.0 million; $0.46 | $19.1 million; $0.32 |
| Net cash used in operations | $27.9 million | $21.7 million |
- Other income was $3.1 million, including $2.8 million of other income, net, primarily reflecting higher interest income on marketable securities. The MSKCC success-payment liability fair-value gain was $0.3 million, versus $1.6 million in Q1 2022.
- Cash, cash equivalents, and marketable securities totaled $291.0 million at March 31, 2023, down from $317.0 million at December 31, 2022. Total assets were $347.5 million; total liabilities were $69.2 million; stockholders’ equity was $278.3 million.
- Cash and cash equivalents decreased $5.6 million during the quarter. Investing activities provided $20.7 million, mainly from marketable-security maturities and sales; financing activities provided $1.6 million, including ATM proceeds.
- No conventional borrowings are identified in the provided balance sheet. Operating lease liabilities totaled $27.4 million. The filing reports no material ongoing financing commitments other than leases and certain license-agreement payments.
- Gross profit and operating margins are not presented; the filing reports licensing and collaboration revenue and operating expenses separately.
Material changes and business developments
- R&D expense rose substantially, primarily due to increased contract manufacturing and research activity, including work on CB-010 and CB-012, and higher personnel costs.
- Revenue growth reflected higher AbbVie agreement revenue ($1.6 million versus $0.9 million) and increased revenue from other licensees. The three largest licensees represented 87.5% of accounts receivable and contract assets at quarter-end.
- Caribou sold 168,635 shares through its ATM program by March 31, 2023, for $1.2 million gross proceeds ($1.0 million net); the program permits up to $100 million in gross sales. Its shelf registration statement permits offerings of up to $400 million, including the ATM capacity.
- Potential future development, regulatory, and sales milestone payments under certain license and assignment agreements totaled approximately $161.2 million; payment depends on specified milestones and other agreement conditions.
Outlook, risks, and contingencies
- Management expects existing cash, cash equivalents, and marketable securities to fund the current operating plan for at least 12 months from the financial-statement issuance date. The company expects continued substantial losses and says it may need additional capital; financing may be unavailable or require dilution or surrender of rights.
- CB-010 is in the ANTLER Phase 1 trial; management planned a safety and efficacy update in the second half of 2023, including at least 15 dose-escalation patients with at least six months of follow-up. CB-011 is in the CaMMouflage Phase 1 trial, with dose-escalation updates expected as it advances. CB-012 remained in IND-enabling studies, with an IND submission planned for the second half of 2023. These are forward-looking plans, not reported outcomes.
- Development, regulatory approval, clinical results, manufacturing capacity, third-party dependence, intellectual-property disputes, and future financing are material uncertainties. The company relies on external manufacturers and service providers and expects expenses to increase as programs advance.
- Putative class actions allege misleading disclosures concerning CB-010’s therapeutic-effect durability and clinical and commercial prospects. One federal case was voluntarily dismissed in March 2023; a new federal case was filed in April, with a consolidation motion pending, and a related California state case was filed in March. Caribou says the claims are without merit and sought a stay of the state case.
- Caribou reported no material indemnification claims or recorded related liabilities. It stated that no material risk-factor changes from its 2022 Form 10-K occurred during the quarter.
Important facts for investors to verify
- Whether clinical updates for CB-010, CB-011, and the planned CB-012 IND submission occurred on the stated timelines, and what the resulting data show.
- Cash burn, investment balances, and runway as R&D spending increases; the runway estimate is based on current operating assumptions.
- Revenue concentration and the timing and durability of collaboration and license revenue, including deferred revenue and remaining performance obligations.
- Potential dilution from ATM or other offerings, and the conditions and likelihood of contingent license milestone payments.
- Progress and potential financial or operational effects of the CB-010-related securities lawsuits.